Friday, 21 Sep 2018

You are here

Surgical Decompression Ineffective for Subacromial Shoulder Pain

Lancet reports that a common surgical intervention, arthroscopic sub-acromial decompression is ineffective compared to arthroscopy or no surgery at all.

A multicentre, randomised, placebo-controlled trial included surgically naive patients who had subacromial pain for > 3 months with intact rotator cuff tendons.  These patients were refractory despite prior exercise therapy and at least one steroid injection. Patients were randomized to receive either A) arthroscopic subacromial decompression, B) arthroscopy only (no removal of bone and soft tissue), or C) no treatment intervention.

The primary outcome was the Oxford Shoulder Score (0 [worst] to 48 [best]) at 6 months.

The study enrolled 313 patients (106 to decompression surgery, 103 to arthroscopy only, and 104 to no treatment).  At 6 months, there was data for 90 patients assigned to decompression, 94 to arthroscopy, and 90 to no treatment.

The Oxford Shoulder Scores did not differ between the two surgical groups at 6 months (decompression mean 32·7 points vs arthroscopy mean 34·2 points). There was little benefit over no treatment (mean 29·4 points). While this was statisticially significant (p=0·0014), such differences were not felt to be clinically meaningful.

There were six study-related frozen shoulders (in two patients in each group) and no other complications.

Surgical intervention for subacromial shoulder pain failed to yield clinically important results and surgical decompression appeared to offer no extra benefit over arthroscopy only. 

These data imply a greater role for conservative management measures when treating subacromial shoulder pain. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Managing Comorbidity and Poor Drug Responses

Comorbidity is pervasive and complicates medical care in general. It can be a by-product of aging. It may result from drug therapy or an inciting disease process and may be part of the constellation that defines the primary disorder. A growing body of evidence that suggests that comorbidity has a significant dampening effect on drug responsiveness and, adds to poorer outcomes in patients with inflammatory arthritis.

Opioid Aversion is Augmenting Spinal Steroid Injections

As physicians turn away from opioids, are they resorting to options that may also be unsafe?

The New York Times reports that some physicians are using the anti-inflammatory drug, Depo-Medrol, for intraspinal injections to manage painful spinal and perispinal disorders.

Company Payments to Rheumatologists, Specialists Linked to Increased ACTH Prescriptions

Despite its exorbitant price tag and paucity of supportive clinical evidence, ACTH (corticotropin) sales have increased in the United States. A recent JAMA article examined its use by specialists and found that those who prescribe ACTH (including rheumatologists, nephrologists, neurologists) received corticotropin-related payments from the products sole manufacturer, Mallinckrod.

Veterans Administration Shuns Marijuana as an Option

Cannabis therapy is legal in 30 states in the US, and soon to be legal in Canada and Great Britian, but the US Veterans Administration continues to reject medical marijuana as a therapeutic option - even in states where it is approved.

Predictors of Methotrexate Non-Response

New research from a UK study suggests that nonresponse to oral or subcutaneous MTX was seen in 43% and is predicted by seronegativity, higher disease activity measures and higher anxiety scores.